Brokers Set Expectations for KYMR Q1 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Analysts at B. Riley issued their Q1 2025 EPS estimates for Kymera Therapeutics in a note issued to investors on Monday, March 3rd. B. Riley analyst K. Patel anticipates that the company will earn ($0.94) per share for the quarter. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics' Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($1.09) EPS and Q4 2025 earnings at ($1.09) EPS.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The firm had revenue of $7.39 million during the quarter, compared to analysts' expectations of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%.

Several other equities analysts have also commented on the company. BTIG Research assumed coverage on Kymera Therapeutics in a research note on Tuesday, December 10th. They issued a "buy" rating and a $60.00 price target on the stock. HC Wainwright upped their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Leerink Partners reaffirmed an "outperform" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. BMO Capital Markets initiated coverage on shares of Kymera Therapeutics in a research report on Friday, December 6th. They set a "market perform" rating and a $55.00 price target for the company. Finally, Wells Fargo & Company upgraded shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $38.00 to $57.00 in a report on Monday, December 2nd. Three investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $56.69.

Remove Ads

Kymera Therapeutics Trading Up 1.1 %

Kymera Therapeutics stock traded up $0.35 during mid-day trading on Tuesday, hitting $32.89. The company's stock had a trading volume of 639,628 shares, compared to its average volume of 584,001. The stock's fifty day moving average is $38.23 and its two-hundred day moving average is $43.40. The firm has a market capitalization of $2.14 billion, a PE ratio of -14.06 and a beta of 2.22. Kymera Therapeutics has a 1 year low of $29.07 and a 1 year high of $53.27.

Hedge Funds Weigh In On Kymera Therapeutics

Several large investors have recently bought and sold shares of the business. Blue Trust Inc. lifted its holdings in Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after buying an additional 270 shares during the last quarter. State of Wyoming purchased a new position in Kymera Therapeutics in the fourth quarter valued at approximately $45,000. GF Fund Management CO. LTD. acquired a new stake in Kymera Therapeutics during the fourth quarter worth approximately $55,000. Quarry LP acquired a new stake in Kymera Therapeutics during the third quarter worth approximately $95,000. Finally, KBC Group NV lifted its position in shares of Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after buying an additional 752 shares during the last quarter.

Insider Activity

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. The trade was a 3.37 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the sale, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,788 shares of company stock worth $455,202. Corporate insiders own 15.82% of the company's stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.